Vaginal cancer survival statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Age

Age that vaginal and vulva cancers survival is highest, 2009-2013, England

 

Five-year survival for vaginal or vulval cancer is highest in the youngest women and decreases with increasing age. Five-year net survival in women ranges from 82% in 15-49 year olds to 55% in 70-89 year-olds for patients diagnosed with vaginal or vulval cancer in England during 2009-2013.[1]

Vaginal or Vulval Cancer (C51, C52), Five-Year Net Survival by Age, England, 2009-2013

References

  1. Muller P, Belot A, Morris M, Rachet B, Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine. Net survival and the probability of cancer death from rare cancers. Available from http://csg.lshtm.ac.uk/rare-cancers/. Accessed July 2016.

About this data

Data is for: England, 2009-2013, ICD-10 C51, C52

Last reviewed:

Five-year relative survival for vaginal and vulval cancer in women in England (60%), Scotland (61%) and Northern Ireland (60%) are above the average for Europe (57%). Wales (57%) is similar to the European average.[1] Across the European countries for which data is available, five-year relative survival in women ranges from 41% (Slovakia) to 65% (The Netherlands).[1

Vaginal and Vulval Cancer (C51, C52.9, C57.8, C57.9), Age-Standardised Five-Year Relative Survival, Females (Aged 15+), European Countries, 2000-2007

Data consists of both observed and predicted 5-year relative survival. Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

Possible explanations for persistent international differences in survival include differences in cancer biology, use of diagnostic tests and screening, stage at diagnosis, access to high-quality care, and data collection practices.[1]

References

  1. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15:23-34

About this data

Data is for: 29 European countries, patients diagnosed in 2000-2007 and followed up to 2008, vaginal and vulval cancer (C51, C52.9, C57.8, C57.9).

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.